Top Net Payout Yield Stocks To Own For 2017

Related EWG Jim Strugger Shares Options Strategies for iShares MSCI Germany Index Fund (ETF) and Diamond Resorts 9 Investment Options For Traders Looking To Add Europe To Their Portfolio

In a new report, HSBC Global Research analyst Rainer Sartoris takes a close look at the impact that a flood of immigrants are having on European economic leader Germany. According to Sartoris, immigrants could cost Germany €33 billion in 2017.

German Prime Minister Angela Merkel opened Germany’s doors to humanitarian crisis refugees from Syria and elsewhere in the Middle East last year. More than a million refugees took advantage of Germany's generosity, but not all Germans were happy with the inflow of refugees. In fact, the rise of right-wing anti-immigration political parties in Germany and throughout Europe is likely due to the recent influx of refugees.

Top Net Payout Yield Stocks To Own For 2017: Sagent Pharmaceuticals Inc.(SGNT)

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. It offers a range of products across anti-infective, oncolytic, and critical care indications in various presentations, including single-and multi-dose vials, pre-filled ready-to-use syringes, and premix bags. The company?s anti-infective products include Levofloxacin, a fluoroquinolone antibacterial for the treatment of various infections caused by susceptible bacteria in adults of age 18 years or older; and Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structure, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients. Its oncology products comprise Gemcitabine, a nucleoside metabolic inhibitor used for the treatment of ovarian, breast, lung, and panc reatic cancers; and Topotecan, a topoisomerase inhibitor for small cell lung cancer sensitive disease. The company also offers critical care products consisting of Adenosine, an antiarrhythmic used for the treatment of cardiac rhythm disturbances; and Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2011, it marketed 33 generic injectable products; and had a new product pipeline that included 36 products represented by 63 Abbreviated New Drug Applications (ANDAs). The company sells its products to pharmaceutical wholesale companies, which then distribute the products to end-user hospitals, long-term care facilities, alternate care sites, and clinics. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Sagent Pharmaceuticals Inc (NASDAQ: SGNT) got a boost, shooting up 40 percent to $21.65 as the company agreed to be acquired by Nichi-Iko Pharmaceutical for $21.75 per share. RBC Capital downgraded Sagent Pharmaceuticals from Outperform to Sector Perform.

Top Net Payout Yield Stocks To Own For 2017: Smith & Nephew SNATS, Inc.(SNN)

 

Smith & Nephew plc develops, manufactures, markets, and sells medical technology products and services worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints; and arthroscopy enabling technologies for healthcare providers, such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures; gynecological instrumentation devices; knee implant products for specialized knee replac ement procedures; and hip implant products for reconstruction of the hip joint, as well as various products and technologies to assist in surgical treatment of the ear, nose, and throat. In addition, the company offers advanced wound care products for the treatment of acute and chronic wounds, including leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound devices, including traditional and single-use negative pressure wound therapy and hydrosurgery systems; and biologics and other bioactive technology products for debridement and dermal repair/regeneration. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

Advisors’ Opinion:

  • [By Charles Carlson, CEO and Portfolio Manager, Horizon Investment Services]

    For investors looking for growth but also income, I especially like three health-care related stocksFresenius Medical (FMS), Novo Nordisk (NVO), and Smith & Nephew (SNN).

Top Railroad Companies To Invest In 2017: Constellation Brands Inc(STZ)

Constellation Brands, Inc., incorporated on December 4, 1972, is an international beverage alcohol company. The Company is a producer and marketer of beer and wine the United States and Canada. The Company’s segments include Beer, Wine and Spirits, and Corporate Operations and Other. The Company’s wine portfolio is complemented by select spirits brands and other select beverage alcohol products. It is a multi-category supplier (beer, wine and spirits) of beverage alcohol in the United States.

The Company owns principal facilities, including the Nava Brewery in Nava, Coahuila, Mexico; the glass production plant in Nava, Coahuila, Mexico; wineries in California, which include the Woodbridge Winery in Acampo and the Mission Bell winery in Madera; the Canandaigua winery in Canandaigua, New York, and the distillery in Lethbridge, Alberta, Canada. It operates over four facilities in the San Diego, California area that produce its Ballast Point brand, including Miram ar, which serves as the primary production site for the brand. In the United States, the Company operates over 20 wineries using varieties of grapes grown in the Napa, Sonoma, Monterey and San Joaquin regions of California. It also operates approximately eight wineries in Canada, over four wineries in New Zealand and approximately five wineries in Italy. The Company’s Canadian whisky requirements are produced and aged at its Canadian distillery in Lethbridge, Alberta.

Beer

The Company sells a number of brands in the import and craft beer categories. Within the imported beer category, the Company has rights to import, market and sell its Mexican Beer Brands in over 50 states of the United States, which include Corona Extra, Corona Light, Modelo Especial, Pacifico, Negra Modelo and Victoria. It also includes Modelo Especial Chelada, which is a blend of beer with flavors of tomato, salt and lime. Its craft beer products are primarily sold under the Bal last Point brand. Ballast Point produces over 40 different s! tyles of beer.

Wine and Spirits

The Company is a producer and marketer of wine. It sells a number of wine brands across various categories, including table wine, sparkling wine and dessert wine, and across all price points, such as popular, premium and luxury categories. The Company owns, leases or has interests in approximately 13,300 acres of vineyards in California (the United States), over 5,800 acres of vineyards in New Zealand, approximately 1,700 acres of vineyards in Canada and over 900 acres of vineyards in Italy.

The Company’s wine produced in the United States is primarily marketed domestically and in Canada. Wine produced in Canada is primarily marketed domestically. Wine produced in New Zealand and Italy is primarily marketed in the United States and Canada. In addition, the Company exports its wine products to other major world markets. Some of its wine and spirits brands sold in the United States include Arbor Mist, Black Box, Blackstone, Clos du Bois, Estancia, Franciscan Estate, Inniskillin, Kim Crawford, Mark West, Mount Veeder, Nobilo, Ravenswood, Rex Goliath, Robert Mondavi, Ruffino, Simi, Toasted Head, Wild Horse, Black Velvet Canadian Whisky and SVEDKA Vodka. In its spirits business, SVEDKA Vodka is imported from Sweden and is the imported vodka brand in the United States.

The Company competes with Anheuser-Busch InBev, MillerCoors, Heineken, Pabst Brewing Company, The Boston Beer Company, E&J Gallo Winery, The Wine Group, Trinchero Family Estates, Treasury Wine Estates, Ste. Michelle Wine Estates, Deutsch Family Wine & Spirits, Jackson Family Wines, Andrew Peller, Kruger Wines and Spirits, Diageo, Beam Suntory, Brown-Forman, Sazerac Company and Pernod Ricard.

Advisors’ Opinion:

  • [By Monica Gerson]

     

    Darden Restaurants, Inc. (NYSE: DRI) is estimated to report its quarterly earnings at $1.08 per share on revenue of $1.81 billion. ConAgra Foods Inc (NYSE: CAG) is expected to report its quarterly earnings at $0.52 per share on revenue of $2.89 billion. Paychex, Inc. (NASDAQ: PAYX) is projected to report its quarterly earnings at $0.49 per share on revenue of $751.52 million. Micron Technology, Inc. (NASDAQ: MU) is expected to post a quarterly loss at $0.09 per share on revenue of $2.95 billion. McCormick & Company, Incorporated (NYSE: MKC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.06 billion. Constellation Brands, Inc. (NYSE: STZ) is expected to report its quarterly earnings at $1.51 per share. Schnitzer Steel Industries, Inc. (NASDAQ: SCHN) is estimated to report its quarterly earnings at $0.18 per share on revenue of $356.41 million. Franklin Covey Co. (NYSE: FC) is expected to post its quarterly earnings at $0.08 per share on revenue of $49.89 million. Lindsay Corporation (NYSE: LNN) is projected to report its quarterly earnings at $0.99 per share on revenue of $148.43 million.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

  • [By Teresa Rivas]

    A better than expected first quarter is fueling gains forConstellation Brands (STZ) on Thursday.

    Reuters

    The spirits maker said it earned $1.54 a share on revenue that climbed 14.8% to $.187 billion. Analysts were expecting earnings of $1.52 a share on revenue of $1.83 billion. Constellation also reaffirmed its full year guidance for earnings per share between $6.05 and $6.35, compared to the $6.27 consensus estimate.

    Wells Fargos Bonnie Herzog reiterated an Outperform rating on the stock following the report:

    Strong pricing growth and mix benefits drove 54bps gross margin and 72bps in operating margin expansion in beer resulting in a record 35.6% beer op margin.Wineshipment volumes were up a solid 4.5% with net pricing of 3.7%, both above our expectations. Mix benefits helped drive a solid 164bps of wine & spirits operating margin expansion.Overall we are encouraged by STZ’s results in both segments, as they reflect the benefits of its strategic investments and strong execution.As planned, STZ completed the next phase of its Nava brewery expansion to provide 20M hl of capacity. Outlook Maintained:Despite the earnings beat, and impressive EPS growth,STZ maintained its guidance for FY17, which we continue to believe remains very conservative, given it implies only 8.1% – 15.3% EPS growth on average for the remaining 3 quarters of the year.Bottom Line: We continue to think STZ has excellent momentum and are encouraged by this quarter’s impressiv e results. While we were somewhat disappointed that management did not raise guidance, we believe underlying trends should support strong results above the current outlook.The stock’s reaction to STZ’s earnings beat could be tempered by guidance being maintained.

    The shares are up 2.4% to $163.14 in recent trading.